Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses

Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses

The COVID-19 pandemic, caused by SARS-CoV-2, prompted global efforts to develop vaccines to control the disease. Various vaccines, including mRNA (BNT162b2, mRNA-1273), adenoviral vector (ChAdOx1, Ad26.COV2.S), and inactivated virus platforms (BBIBP-CorV, CoronaVac), elicit high-titer, protective an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Engin Berber, Ted M. Ross
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Vaccines
Subjects:	COVID-19 SARS-CoV-2 vaccines humoral immune response vaccine effectiveness longevity
Online Access:	https://www.mdpi.com/2076-393X/12/11/1284
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of Baseline Blood Zinc Levels on the Humoral Immune Response After COVID-19 mRNA Vaccination: A Prospective Study in a Japanese Population
by: Mohammad Said Ashenagar, et al.
Published: (2024-11-01)

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months
by: Seçil Yılmaz, et al.
Published: (2025-04-01)

Dynamics of humoral immunity during natural SARS-CoV-2 infection and/or after vaccination with the ‘Sputnik V’ vaccine
by: A. V. Ivanov, et al.
Published: (2024-11-01)

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response
by: Ali Toloue Ostadgavahi, et al.
Published: (2021-05-01)

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Radiation–Oncology Patients: A Systematic Review and Meta-Analysis
by: Paul Thöne, et al.
Published: (2025-06-01)

Humoral Response to SARS-CoV-2 Vaccine-Boost in Cancer Patients: A Case Series from a Southern European Cancer Center
by: Júlio Oliveira, et al.
Published: (2024-10-01)

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination
by: Rahul K. Suryawanshi, et al.
Published: (2023-12-01)

SARS-CoV-2 Infection Enhances Humoral Immune Response in Vaccinated Liver Transplant Recipients
by: Jan Basri Adiprasito, et al.
Published: (2024-09-01)

Hybrid immunity and host factors: implications on serostatus induced by COVID-19 vaccines
by: Franklin E. Torres-Jiménez, et al.
Published: (2025-07-01)

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273
by: Alejo Erice, et al.
Published: (2025-03-01)

Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate
by: Marcin Bazylewicz, et al.
Published: (2025-01-01)

The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
by: Ji Young Park, et al.
Published: (2025-02-01)

SARS-CoV-2-specific humoral and cellular immunity assessment in Peruvian vaccinated population: a cross-sectional study
by: Marlon Yuri Garcia-Paitan, et al.
Published: (2025-07-01)

Chronic heart failure and hypoalbuminemia are risk factors of poorer mRNA SARS-CoV-2 vaccine response in maintenance Hemodialysis patients (the COVaccinDia study)
by: Pierre Laurent, et al.
Published: (2025-06-01)

Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination1
by: Hongyu Wang, et al.
Published: (2023-12-01)

Humoral response to anti-COVID immunization and SARS-CoV-2 infection in HIV-infected persons
by: Marić Daniela, et al.
Published: (2025-01-01)

Humoral response against COVID-19 in the population of western region of Poland
by: Dominika Siedlecka, et al.
Published: (2025-08-01)

One year of COVID-19 vaccination
by: Cheng Meng-Li, et al.
Published: (2022-03-01)

COVID-19 hospitalization in vaccinated and non-vaccinated patients: Clinical profile and outcomes
by: Laura Holtman-Ferreira, et al.
Published: (2025-05-01)

Humoral and Cell-Mediated Immunity Against SARS-CoV-2 in Healthcare Personnel Who Received Multiple mRNA Vaccines: A 4-Year Observational Study
by: Hideaki Kato, et al.
Published: (2025-04-01)

Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron
by: Andrew H. Karaba, et al.
Published: (2025-02-01)

SARS-CoV-2 vaccine-elicited immune responses in solid organ transplant recipients
by: Euri Seo, et al.
Published: (2024-12-01)

Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections
by: Engin Berber, et al.
Published: (2025-12-01)

Humoral and Cellular Immune Responses to SARS-CoV-2 in Participants with Head and Neck Cancer
by: Luminita Mărutescu, et al.
Published: (2025-06-01)

Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models
by: Prajakta Warang, et al.
Published: (2025-12-01)

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history
by: Rui Wang, et al.
Published: (2025-08-01)

Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications
by: Yu Chen, et al.
Published: (2024-12-01)

Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines
by: Luísa Vilela, et al.
Published: (2024-11-01)

Monitoring humoral responses against three SARS-CoV-2 vaccines in a university population from Chihuahua, Mexico
by: Inés V Chavarría-Bencomo, et al.
Published: (2024-09-01)

Sindbis Virus Replicon-Based SARS-CoV-2 and Dengue Combined Vaccine Candidates Elicit Immune Responses and Provide Protective Immunity in Mice
by: Yihan Zhu, et al.
Published: (2024-11-01)

SARS-CoV-2 Variant-Specific Antibodies in Vaccinated Inflammatory Bowel Disease Patients
by: Eva Ulla Lorentzen, et al.
Published: (2025-05-01)

Efficacy of Inactivated Bivalent SARS-CoV-2 Vaccines Targeting Ancestral Strain (ERAGEM), Delta, and Omicron Variants
by: Busra Kaplan, et al.
Published: (2025-02-01)

Vaccination Strategies: Mixing Paths Versus Matching Tracks
by: Achilleas Livieratos, et al.
Published: (2025-03-01)

SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023
by: Marjut Sarjomaa, et al.
Published: (2025-06-01)

COVID-19 vaccines: Immune correlates and clinical outcomes
by: Shant H. Mahrokhian, et al.
Published: (2024-12-01)

Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer
by: K.L. Juliëtte Schmidt, et al.
Published: (2024-12-01)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
by: Li Guo, et al.
Published: (2023-12-01)

Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination
by: Davide Torre, et al.
Published: (2025-05-01)

Longitudinal Comparison of Three T-Cell Assays and Three Antibody Assays Against SARS-CoV-2 Following Homologous mRNA-1273/mRNA-1273/mRNA-1273 and Heterologous ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naïve Healthcare Workers
by: Hyeyoung Lee, et al.
Published: (2024-11-01)

A vaccine is not too far for COVID-19
by: Shailesh Kumar Patel, et al.
Published: (2020-05-01)